Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children.
A highly attenuated respiratory syncytial virus (RSV) experimental vaccine, RSV ts-2, was sequentially evaluated in adults, seropositive children, and finally, fully susceptible seronegative children. The vaccine was administered intranasally in doses ranging from 10(5.2) to 10(6.3) PFU/ml. In both adults and children, the vaccine proved to be poorly infectious. Although poor infectivity would not have been predicted from tissue culture studies of RSV ts-2 growth, the human experience closely parallels the experience in a series of animal models, including the chimpanzee. The poor infectivity of this RSV vaccine virus preparation suggests that the postulated defect in the RSV ts-2 fusion protein may be important in determining in vivo infectivity of RSV.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D007223:Infant; D009154:Mutation; D012136:Respiratory Syncytial Viruses / Q000235:genetics / Q000276:immunology*; D013696:Temperature; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage; D014765:Viral Vaccines / Q000008:administration & dosage
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines